HORAN Wealth LLC Decreases Stock Position in Johnson & Johnson $JNJ

Key Points

• HORAN Wealth cut its Johnson & Johnson position by 51.5% in the second quarter, selling 25,391 shares and retaining 23,953 shares valued at approximately $6.1 million. Institutional investors collectively own 69.55% of J&J.
• Insiders have been net sellers: executives sold 87,569 shares worth roughly $23.1 million over the past quarter, while insiders own just 0.16% of the company.
• Despite mixed ownership activity and a failed mid-stage depression-drug trial, Wall Street maintains a “Moderate Buy” consensus with an average price target of $274.13. J&J recently exceeded quarterly earnings and revenue estimates, pays a $1.34 quarterly dividend, and is supported by oncology momentum and potential value from a DePuy Synthes divestiture.

HORAN Wealth LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 51.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,953 shares of the company's stock after selling 25,391 shares during the period. Johnson & Johnson makes up 0.8% of HORAN Wealth LLC's portfolio, making the stock its 26th biggest position. HORAN Wealth LLC's holdings in Johnson & Johnson were worth $6,084,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. Elefante Mark B increased its holdings in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after acquiring an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC lifted its stake in Johnson & Johnson by 76.1% during the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock worth $3,697,000 after purchasing an additional 6,539 shares during the last quarter. Gradient Investments LLC boosted its holdings in Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares during the period. Louisiana State Employees Retirement System bought a new stake in Johnson & Johnson during the first quarter valued at $30,017,000. Finally, WealthShield Partners LLC increased its stake in Johnson & Johnson by 86.0% during the first quarter. WealthShield Partners LLC now owns 13,121 shares of the company's stock valued at $3,207,000 after purchasing an additional 6,066 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Bank of America raised their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a research report on Friday, July 10th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. UBS Group initiated coverage on Johnson & Johnson in a report on Wednesday, September 2nd. They set a "buy" rating and a $320.00 target price for the company. Royal Bank Of Canada increased their price target on Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Finally, Argus set a $300.00 price objective on Johnson & Johnson in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $274.13.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Potential $20 billion DePuy Synthes sale could unlock value. Apollo Global Management is reportedly in talks to acquire J&J’s DePuy Synthes orthopedics business, which generated approximately $9.3 billion in 2025 revenue. A sale or spinoff could sharpen J&J’s focus and return capital to shareholders. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Positive Sentiment: Rybrevant delivers strong lung-cancer results. J&J reported that Rybrevant plus chemotherapy produced a 34.3-month median overall survival in EGFR exon 20 insertion-positive non-small-cell lung cancer, described as the longest reported result for this population. Separate data also showed fewer treatment-related events with the Rybrevant Faspro and Lazcluze combination, supporting the oncology pipeline and potential commercial momentum. Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
• Positive Sentiment: Analyst and defensive-investment support remain favorable. TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and the possible DePuy Synthes transaction. J&J is also being highlighted as a reliable dividend and defensive healthcare holding, which may attract investors during market volatility. J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Buy Rating
• Neutral Sentiment: Investors are monitoring strategic and fundamental developments. Attention is focused on J&J’s ability to achieve double-digit growth while Stelara faces biosimilar competition. Recent institutional activity has been mixed, while reported insider transactions consisted entirely of sales over the past six months.
• Negative Sentiment: Clinical setback hits a partnered depression treatment. JNJ-5120, also known as PIPE-307, failed to meet the primary endpoint in the Phase 2 MOONLIGHT-1 trial for major depressive disorder. J&J is reviewing additional data, but the failure reduces confidence in this portion of its drug-development pipeline. Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Johnson & Johnson Trading Up 0.2%

Johnson & Johnson stock opened at $266.94 on Wednesday. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $643.29 billion, a price-to-earnings ratio of 30.93, a PEG ratio of 2.54 and a beta of 0.24. The firm has a 50-day moving average price of $263.17 and a two-hundred day moving average price of $246.23.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is presently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.